Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. root
  2. XOFIGO
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

XOFIGO

Medicine - Posted on Sep 06 2019
Active substance (DCI)
  • dichlorure de radium (Ra-223)
history (4)
  • 7/17/19

    XOFIGO (dichlorure de radium (Ra-223))

    XOFIGO (dichlorure de radium (Ra-223))
    CAV :
    54321
    icône flèche
  • 6/22/16

    XOFIGO (radium), radioisotope

    Minor clinical added value relative to placebo in the treatment of castration-resistant prostate cancer, with symptomatic bo...
    CAV :
    54321
    icône flèche
  • Economic analysis
    4/2/14

    XOFIGO (radium dichloride), radioisotope

    Minor improvement in the treatment of castration-resistant prostate cancer, with symptomatic bone metastases and no known vi...
    CAV :
    54321
    icône flèche
Technical information
ATC code
  • V10XX03
Manufacturer
BAYER HEALTHCARE SAS
Presentation

XOFIGO 1000 kBq/mL, solution injectable (code CIS : 66302387)
1 flacon(s) en verre de 6 ml - Code Code CIP : 34009 585 762 7 0

All our publications
    Drug therapy Genital cancers Health economics Radiotherapy and physical agents

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
UykNd19cF8XqMqCw